重症筋無力症(MG)治療薬のパイプライン分析

P&S Market Researchが発行した調査報告書(PSM802122)
◆英語タイトル:Myasthenia Gravis Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments
◆商品コード:PSM802122
◆発行会社(リサーチ会社):P&S Market Research
◆発行日:2017年9月1日
◆ページ数:102
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Group License(5名様閲覧用)USD3,250 ⇒換算¥357,500見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,000 ⇒換算¥770,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はP&S Market Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。P&S Market Research社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

The study analysed that the therapeutics pipeline comprises of approximately 19 drug candidates in different stages of development. Myasthenia gravis is a chronic autoimmune disorder that acts on neuromuscular junction and leads to the weakening of skeletal muscles. This causes loss of muscle control in moving the body parts, such as the movement of arms and legs, breathing, loss of eye movements, chewing, talking, and swallowing. The situation of the disease worsens after a period of activity and improves after a period of rest.
Strategic Collaboration for the Development of Myasthenia Gravis Therapeutics

Various companies, educational institutes and medical organizations are collaborating for the development of drugs for the treatment of this disease. For instance, Merck & Co., Inc. entered into a multi-targeted collaboration and license agreement with Ra Pharmaceuticals, Inc. to use the latter’s drug discovery technology platform for the development of orally available cyclic peptides for the treatment of myasthenia gravis.

Various Drug Candidates are Being Developed as Biologics

It has been observed that most of the drugs in the myasthenia gravis therapeutics pipeline, are being developed from the natural source. NT-1654 is a heparan sulfate proteoglycan, and is under development by Neurotune AG for the treatment of myasthenia gravis. The drug acts as a neuromuscular junction stimulator.

Some of the key players developing drugs for the treatment of myasthenia gravis include Alexion Pharmaceuticals, Inc., CSL Behring LLC, Novartis AG and others.

【レポートの目次】

Chapter 1. Research Background

1.1. Research Objectives

1.2. Definition

1.3. Research Scope

1.3.1. Pipeline Analysis by Phase

1.3.2. Pipeline Analysis by Route of Administration

1.3.3. Pipeline Analysis by Molecule Type

1.4. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research

2.2. Primary Research

2.2.1. Breakdown of Primary Research Respondents

2.2.1.1. By industry participants

2.2.1.2. By company type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1. Overview

4.1.1. Signs and Symptoms

4.1.2. Pathophysiology

4.1.3. Diagnosis

4.1.4. Treatment

4.1.5. Epidemiology

4.2. Key Drivers

4.3. Key Barriers

4.4. Pipeline Analysis

4.4.1. Pipeline Analysis by Phase

4.4.2. Pipeline Analysis by Molecule Type

4.4.3. Pipeline Analysis by Route of Administration

4.4.4. Pipeline Analysis by Company

Chapter 5. Pipeline Analysis by Phase

5.1. Pre-registration/Registration: Drug Profiles

5.1.1. Pre-Clinical Studies

5.1.2. Clinical Trials

5.1.3. Clinical Results

5.1.4. Strategic Developments

5.1.5. Designations

5.1.6. Grants

5.1.7. Patents

5.1.8. Technology

5.2. Phase III: Drug Profiles

5.2.1. Pre-Clinical Studies

5.2.2. Clinical Trials

5.2.3. Clinical Results

5.2.4. Strategic Developments

5.2.5. Designations

5.2.6. Grants

5.2.7. Patents

5.2.8. Technology

5.3. Phase II: Drug Profiles

5.3.1. Pre-Clinical Studies

5.3.2. Clinical Trials

5.3.3. Clinical Results

5.3.4. Strategic Developments

5.3.5. Designations

5.3.6. Grants

5.3.7. Patents

5.3.8. Technology

5.4. Phase I: Drug Profiles

5.4.1. Pre-Clinical Studies

5.4.2. Clinical Trials

5.4.3. Clinical Results

5.4.4. Strategic Developments

5.4.5. Designations

5.4.6. Grants

5.4.7. Patents

5.4.8. Technology

5.5. Pre-Clinical: Drug Profiles

5.5.1. Pre-Clinical Studies

5.5.2. Strategic Developments

5.5.3. Designations

5.5.4. Grants

5.5.5. Patents

5.5.6. Technology

5.6. Discovery: Drug Profiles

5.6.1. Strategic Developments

5.6.2. Designations

5.6.3. Grants

5.6.4. Patents

5.6.5. Technology

5.7. Inactive: Drug Profiles

5.7.1. Pre-Clinical Studies

5.7.2. Clinical Trials

5.7.3. Clinical Results

5.7.4. Strategic Developments

5.7.5. Designations

5.7.6. Grants

5.7.7. Patents

5.7.8. Technology

5.8. Discontinued: Drug Profiles

5.8.1. Pre-Clinical Studies

5.8.2. Clinical Trials

5.8.3. Clinical Results

5.8.4. Strategic Developments

5.8.5. Designations

5.8.6. Grants

5.8.7. Patents

5.8.8. Technology

Chapter 6. Clinical Trials Analysis

6.1. Clinical Trials by Region

6.2. Clinical Trials by Trial Status

Chapter 7. Competitive Landscape Analysis

7.1. Key Players Benchmarking

7.2. SWOT Analysis

Chapter 8. Company Profiles

8.1 Business Overview

8.2 Product and Service Offerings

Chapter 9. Appendix

9.1 Abbreviations

Note: Certain sections of the above table of contents would vary according to the availability of information.



【レポートのキーワード】

重症筋無力症(MG)

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 重症筋無力症(MG)治療薬のパイプライン分析(Myasthenia Gravis Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆